 <h1>Tazemetostat Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tazemetostat: oral tablets</i></p><p>Side effects include:</p><p>Epithelioid sarcoma: Pain, fatigue, nausea, decreased appetite, vomiting, constipation, anemia, lymphocytopenia. </p><p>Follicular lymphoma: Fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain, lymphocytopenia, hyperglycemia, leukopenia, neutropenia, thrombocytopenia, anemia. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tazemetostat: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin decreased (49%), decreased lymphocytes (36%), white blood cell count decreased (19%), hemorrhage (e.g., wound hemorrhage, rectal hemorrhage, pulmonary hemorrhage, hemorrhage intracranial, cerebral hemorrhage, hemoptysis) (18%), anemia (16%), partial thromboplastin time increased (15%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Triglycerides increased (36%), glucose increased (33%), sodium decreased (30%), phosphate decreased (28%), anorexia (26%), albumin decreased (23%), alkaline phosphatase increased (23%), potassium decreased (20%), weight loss (16%), calcium decreased (16%), glucose decreased (16%), potassium increased (12%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Aspartate aminotransferase increased (18%), alanine aminotransferase increased (14%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Secondary malignancies (e.g., myelodysplastic syndrome [MDS], acute myeloid leukemia [AML])<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (18%), dyspnea/dyspnea exertional (16%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (e.g., tumor pain, pain in extremity, non-cardiac chest pain, flank pain, back pain, arthralgia, bone pain, cancer pain, musculoskeletal pain, myalgia, neck pain) (52%), fatigue/asthenia (47%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) were pain, fatigue, nausea, decreased appetite, vomiting, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (14%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (36%), vomiting (24%), constipation (21%), diarrhea (16%), abdominal pain (13%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Tazverik (tazemetostat)." Epizyme, Inc, Cambridge, MA. </p><h2>More about tazemetostat</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tazemetostat &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Epithelioid Sarcoma</li>
<li>Follicular Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>